BACKGROUND: Survivors of childhood acute lymphoblastic leukemia (ALL) are at an increased risk of developing secondary malignant neoplasms. Radiation and chemotherapy can cause mutations and cytogenetic abnormalities and induce genomic instability. Host immunity and appropriate DNA damage responses are critical inhibitors of carcinogenesis. Therefore, we sought to determine the long-term effects of ALL treatment on immune function and response to DNA damage. METHODS: Comparative studies on 14 survivors in first complete remission and 16 siblings were conducted. RESULTS: In comparison to siblings on the cells that were involved in adaptive immunity, the patients had either higher numbers (CD19+ B cells and CD4+CD25+ T regulatory cells) or similar numbers (alphabetaT cells and CD45RO+/RA- memory T cells) in the blood. In contrast, patients had lower numbers of all lymphocyte subsets involved in innate immunity (gammadeltaT cells and all NK subsets, including KIR2DL1+ cells, KIR2DL2/L3+ cells, and CD16+ cells), and lower natural cytotoxicity against K562 leukemia cells. Thymopoiesis was lower in patients, as demonstrated by less CD45RO-/RA+ naïve T cell and less SjTREC levels in the blood, whereas the Vbeta spectratype complexity score was similar. Array of gene expression response to low-dose radiation showed that about 70% of the probesets had a reduced response in patients. One of these genes, SCHIP-1, was also among the top-ranked single nucleotide polymorphisms (SNPs) during the whole-genome scanning by SNP microarray analysis. CONCLUSION: ALL survivors were deficient in innate immunity, thymopoiesis, and DNA damage responses to radiation. These defects may contribute to their increased likelihood of second malignancy. Copyright (c) 2010 Elsevier Ltd. All rights reserved.
BACKGROUND: Survivors of childhood acute lymphoblastic leukemia (ALL) are at an increased risk of developing secondary malignant neoplasms. Radiation and chemotherapy can cause mutations and cytogenetic abnormalities and induce genomic instability. Host immunity and appropriate DNA damage responses are critical inhibitors of carcinogenesis. Therefore, we sought to determine the long-term effects of ALL treatment on immune function and response to DNA damage. METHODS: Comparative studies on 14 survivors in first complete remission and 16 siblings were conducted. RESULTS: In comparison to siblings on the cells that were involved in adaptive immunity, the patients had either higher numbers (CD19+ B cells and CD4+CD25+ T regulatory cells) or similar numbers (alphabetaT cells and CD45RO+/RA- memory T cells) in the blood. In contrast, patients had lower numbers of all lymphocyte subsets involved in innate immunity (gammadeltaT cells and all NK subsets, including KIR2DL1+ cells, KIR2DL2/L3+ cells, and CD16+ cells), and lower natural cytotoxicity against K562leukemia cells. Thymopoiesis was lower in patients, as demonstrated by less CD45RO-/RA+ naïve T cell and less SjTREC levels in the blood, whereas the Vbeta spectratype complexity score was similar. Array of gene expression response to low-dose radiation showed that about 70% of the probesets had a reduced response in patients. One of these genes, SCHIP-1, was also among the top-ranked single nucleotide polymorphisms (SNPs) during the whole-genome scanning by SNP microarray analysis. CONCLUSION: ALL survivors were deficient in innate immunity, thymopoiesis, and DNA damage responses to radiation. These defects may contribute to their increased likelihood of second malignancy. Copyright (c) 2010 Elsevier Ltd. All rights reserved.
Authors: M Girardi; D E Oppenheim; C R Steele; J M Lewis; E Glusac; R Filler; P Hobby; B Sutton; R E Tigelaar; A C Hayday Journal: Science Date: 2001-09-20 Impact factor: 47.728
Authors: R Haupt; T R Fears; L L Robison; J L Mills; H S Nicholson; L K Zeltzer; A T Meadows; J Byrne Journal: JAMA Date: 1994-11-09 Impact factor: 56.272
Authors: M D Hazenberg; S A Otto; J W Cohen Stuart; M C Verschuren; J C Borleffs; C A Boucher; R A Coutinho; J M Lange; T F Rinke de Wit; A Tsegaye; J J van Dongen; D Hamann; R J de Boer; F Miedema Journal: Nat Med Date: 2000-09 Impact factor: 53.440
Authors: M Jankovic; P Brouwers; M G Valsecchi; A Van Veldhuizen; J Huisman; R Kamphuis; A Kingma; W Mor; J Van Dongen-Melman; L Ferronato Journal: Lancet Date: 1994-07-23 Impact factor: 79.321
Authors: Reiko Ito; Laura P Hale; Susan M Geyer; Jie Li; Andrew Sornborger; Junko Kajimura; Yoichiro Kusunoki; Kengo Yoshida; Marcel R M van den Brink; Seishi Kyoizumi; Nancy R Manley; Kei Nakachi; Gregory D Sempowski Journal: Radiat Res Date: 2017-03-20 Impact factor: 2.841
Authors: Tsz-Kwong Man; Geraldine Aubert; Melissa A Richard; Wanda LeJeune; Elmira Hariri; Tatiana Goltsova; Amos Gaikwad; Yan Chen; Jillian Whitton; Wendy M Leisenring; Michael A Arnold; Joseph P Neglia; Yutaka Yasui; Leslie L Robison; Gregory T Armstrong; Smita Bhatia; Maria M Gramatges Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-11-15 Impact factor: 4.090
Authors: Joanna L Perkins; Yan Chen; Anne Harris; Lisa Diller; Marilyn Stovall; Gregory T Armstrong; Yutaka Yasui; Leslie L Robison; Charles A Sklar Journal: Cancer Date: 2014-05-13 Impact factor: 6.860
Authors: B M Triplett; D R Shook; P Eldridge; Y Li; G Kang; M Dallas; C Hartford; A Srinivasan; W K Chan; D Suwannasaen; H Inaba; T E Merchant; C-H Pui; W Leung Journal: Bone Marrow Transplant Date: 2015-02-09 Impact factor: 5.483
Authors: Fabian Wolpert; Michael A Grotzer; Felix Niggli; Dieter Zimmermann; Elisabeth Rushing; Beata Bode-Lesniewska Journal: Sarcoma Date: 2016-07-25